DA 302168 S
Alternative Names: DA-168; DA-302168-SLatest Information Update: 06 Sep 2024
Price :
$50 *
At a glance
- Originator Chengdu DIAO Pharmaceutical Group
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
Most Recent Events
- 01 Aug 2024 Chendu DIAO Pharmaceutical Group plans a phase I trial for Obesity in China (PO, Tablet) in September 2024 (NCT06541730)
- 18 Jul 2024 Phase-I clinical trials in Obesity (In volunteers) in China (PO) (NCT06534346)
- 18 Apr 2024 Chengdu DIAO Pharmaceutical Group initiates the phase I trial for Obesity ( In volunteers) in China (PO) (NCT06534320)